GleamWall
中文EN

MDCX Medicus Pharma Ltd.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1997296 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-42.4%
TTM EPS YoY160.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-415.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets172.2%
Debt / equity—
Current ratio0.65x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-101.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.95M$4.91M$2.70M$2.59M$1.68M$1.44M$2.01M$1.37M
SG&A expense$2.51M$6.57M$5.89M$5.20M$5.02M$4.58M$3.12M$2.22M
Operating income-$14.46M-$11.48M-$8.60M-$7.79M-$15.43M-$6.02M-$5.13M-$3.59M
Interest expense—$205,638$374,712——$0$0—
Net income-$15.18M-$11.62M-$9.04M-$15.07M-$20.94M-$6.18M-$5.10M-$3.54M
EPS (basic)-11.64-0.21-0.31—-56.18-0.43-0.42—
EPS (diluted)-11.64-0.21-0.31—-56.18-0.43-0.42—
Weighted avg. shares (diluted)1.30M55.06M29.54M—372,63314.28M12.24M—
Banking
Net interest income-$712,652——-$272,824$11,572$40,004—$48,897
Balance sheet
Cash & equivalents$5.02M$15.17M$6.37M$8.71M$8.66M$9.67M$3.98M$4.16M
Current assets$6.37M$16.98M$7.28M$9.89M$9.78M$11.00M$5.09M$5.38M
Total assets$14.54M$27.12M$7.43M$10.06M$9.98M$11.93M$5.66M$5.65M
Current liabilities$9.74M$10.84M$5.95M$9.94M$10.66M$8.54M$3.34M$2.31M
Short-term debt——$2.34M$5.25M$6.79M$4.70M—$0
Total liabilities$25.03M$28.84M$6.00M$10.02M$10.78M$8.69M$3.51M$2.51M
Shareholders' equity-$10.54M-$1.76M$1.33M-$67,554-$910,126$3.25M$2.15M$3.13M
Shares outstanding1.85M60.17M40.00M503,52620.97M15.94M13.42M11.82M
Cash flow statement
Operating cash flow-$15.94M-$6.98M-$8.97M-$6.61M-$6.76M-$5.47M-$3.94M-$3.19M
Investing cash flow———$0———$0
Financing cash flow$3.89M$25.53M$6.83M$6.65M$10.37M$11.16M$3.76M$2.05M
Stock-based compensation$131,775$1.41M$599,306$429,712$852,757$117,448$112,277$91,724

Free plan shows the latest 8 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.